好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Psychosis in Early Onset Parkinson’s Disease: A Population-based Study in Southeast Minnesota
Movement Disorders
P9 - Poster Session 9 (11:45 AM-12:45 PM)
5-017

Our study aims to determine the prevalence of psychosis in EOPD, explore its temporal relationship with PD onset, identify risk factors, assess its impact on all-cause mortality, and evaluate how antipsychotics and SSRIs affect mortality in EOPD patients with psychosis.

Early Onset Parkinson’s Disease (EOPD), defined as Parkinson’s disease (PD) diagnosed before age 50, often presents unique challenges compared to its late-onset counterpart, particularly with regard to non-motor symptoms such as psychosis. Psychosis in EOPD is associated with increased functional impairments and may lead to a higher mortality risk.

Our cohort includes 829 patients with EOPD diagnosed between January 1969 to October 2021 in Olmsted County, Minnesota. EOPD was defined as PD onset at or before the age of 50. Psychosis was defined based on the NINDS/NIMH Work Group clinical criteria, and its association with all-cause mortality was assessed using Cox proportional hazards models. Secondary analyses examined the effects of antipsychotic medications and SSRIs on mortality risk among patients who developed psychosis.
Of 829 patients with EOPD, 158 (19.1%) developed psychosis at a median of 12.1 years after PD onset. Psychosis was significantly associated with a higher risk of death in unadjusted (HR = 4.31, 95% CI: 2.59–7.18, p < 0.001) and adjusted (HR = 3.55, 95% CI: 2.10–6.01, p < 0.001) models. Among psychotic patients, 46.8% were treated with antipsychotic medications, and 46.2% with SSRIs. No significant difference in mortality risk was observed between patients treated with antipsychotics or SSRIs versus those who were not.

Psychosis is a common complication in EOPD and is associated with a significant increase in all-cause mortality. The use of antipsychotics and SSRIs did not significantly alter the mortality risk in these patients. Further research is needed to understand the mechanisms driving this association and to develop tailored interventions.
Authors/Disclosures
Mohamed Derhab, MD, MBBCH (mayo clinic)
PRESENTER 		Dr. Derhab has nothing to disclose.
Ali Zare Dehnavi, MD (Mayo Clinic) Dr. Zare Dehnavi has nothing to disclose.
Aidan Mullan (Mayo Clinic) Aidan Mullan has nothing to disclose.
Emanuele Camerucci, MD (Kansas University Medical Center) Dr. Camerucci has nothing to disclose.
Pierpaolo Turcano, MD (Rush University Medical Center) Dr. Turcano has nothing to disclose.
Khaled Ghoniem, MD (Mayo Clinic) Dr. Ghoniem has nothing to disclose.
James H. Bower, MD, MSc, FAAN (Mayo Clinic) The institution of Dr. Bower has received research support from Abbvie.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic) The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.